The global multiomics market, encompassing genomics, proteomics, metabolomics, and transcriptomics, was valued at approximately USD 2,426.21 million in 2023. It is projected to grow at a compound annual growth rate (CAGR) of 15.3% from 2024 to 2032, reaching an estimated USD 8,696.36 million by 2032.
Market Growth Drivers
- Technological Advancements: Innovations in single-cell analysis and high-throughput sequencing have enhanced the precision and efficiency of multiomics studies, driving market growth.
- Rising Demand for Personalized Medicine: The shift towards tailored therapeutic approaches has increased the adoption of multiomics to understand individual disease profiles.
- Increasing Prevalence of Chronic Diseases: The growing incidence of conditions like cancer and cardiovascular diseases necessitates comprehensive molecular analyses, boosting the demand for multiomics solutions.
- Government Initiatives and Funding: Supportive policies and increased funding for omics research have facilitated market expansion.
Download Free Sample PDF Copy of the Report:
https://www.polarismarketresearch.com/industry-analysis/multiomics-market/request-for-sample
Some of the major players operating in the global multiomics market include
- BD
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- Danaher (Beckman Coulter)
- PerkinElmer, Inc.
- Shimadzu Corporation
- Bruker
- QIAGEN
- Agilent Technologies, Inc.
- BGI Genomics
Key Trends
- Integration with Artificial Intelligence (AI): The incorporation of AI and machine learning algorithms in multiomics data analysis enhances predictive accuracy and accelerates research outcomes.
- Adoption of Cloud-Based Platforms: Cloud computing offers scalable storage and processing capabilities, enabling efficient handling of large omics datasets.
- Expansion into New Application Areas: Beyond healthcare, multiomics is finding applications in agriculture, environmental studies, and nutrition, broadening its market scope.
Research Scope
Market Segmentation:
The research report categorizes the market into various segments and sub-segments. The primary segments covered in the study include Product & Service, application, Platform, Type. The splitting of the market into various groups enables businesses to understand market preferences and trends better.
Multiomics Market, Product & Service Outlook (Revenue – USD Million, 2019-2032)
- Products
- Instruments
- Consumables
- Software Artillery Shells
- Services
Multiomics Market, Application Outlook (Revenue – USD Million, 2019-2032)
- Cell Biology
- Oncology
- Neurology
- Immunology
Multiomics Market, Platform Outlook (Revenue – USD Million, 2019-2032)
- Genomics
- Transcriptomics
- Proteomics
- Metabolomics
- Integrated Omics Platforms
Multiomics Market, Type Outlook (Revenue – USD Million, 2019-2032)
- Single-cell Multi-omics
- Bulk Multi-omics
Geographical Analysis: North America holds the largest market share, attributed to advanced research infrastructure and significant investments. The Asia-Pacific region is expected to witness the fastest growth due to increasing healthcare expenditures and research activities.
Future Outlook
The multiomics market is poised for substantial growth, with projections indicating a market size of approximately USD 8.69 billion by 2032, growing at a CAGR of 15.3% from 2024.
Emerging markets, particularly in Asia-Pacific, present significant opportunities due to expanding research capabilities and healthcare investments. However, challenges such as high costs of instruments and data storage, along with complex regulatory requirements, may impede growth.
Recent Developments in the Industry
- January 2024: Akoya Biosciences entered into a license and distribution agreement with Thermo Fisher Scientific to integrate Akoya’s PhenoImager® systems and PhenoCode™ reagents with Thermo Fisher’s ViewRNA In Situ Hybridization Assays. This collaboration aims to streamline workflows for whole-slide, multiomic imaging, enhancing the detection of protein and RNA biomarkers in tissue samples.
- April 2023: Mission Bio partnered with Fulgent Genetics to incorporate Mission Bio’s Tapestri® Platform into Fulgent’s service offerings. This integration enables pharmaceutical developers to utilize single-cell multi-omics for biomarker discovery, clinical research, and measurable residual disease (MRD) assessment, thereby advancing precision oncology and accelerating drug development.
These strategic collaborations reflect the industry’s commitment to advancing multi-omics technologies, providing researchers and clinicians with comprehensive tools for deeper insights into complex diseases and the development of targeted therapies.